美国Xcellerex
总部位于马萨诸塞州的Xcellerex拥有135名雇员，其营收大约为5000万美元。该公司获得的风险资本投资包括Kleiner Perkins Caufield & Byers、VantagePoint Venture Partners和SCG Capital。

Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized.

Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. The Xcellerex platform transforms biomanufacturing economics by enabling:

Faster deployment of new manufacturing capacity: 12-18 months vs. 3-5 years.

Reduced capital investment: Typical savings of 50% to 70% compared to conventional approaches.

Unmatched flexibility: Modular microenvironment approach enables fast, low-cost redeployment for multi-drug production.

Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of single-use bioreactors, PDMax® high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also actively seeks creative partnerships to facilitate access to the platform.